In the clinical trial of the new drug, sacituzumab govitecan, about a third of the patients responded to treatment and the effect lasted up to eight months. The research was funded by the drug's maker.
Read More
Aggressive Breast Cancer Responds to New Drug
Read More
Subscribe to:
Post Comments (Atom)
0 Response to "Aggressive Breast Cancer Responds to New Drug"
Post a Comment